Skip to main content

BI 1199.248 INBUILD-ON An open label extension trial of the long term safety of nintedanib in patients with progressive fibrosing interstitial lung disease.

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Boehringer Ingelheim Corporation

Start Date

May 8, 2019

End Date

March 31, 2023
 

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Boehringer Ingelheim Corporation

Start Date

May 8, 2019

End Date

March 31, 2023